Association Between Angiotensin II Receptor Blockers and the Risk of Lung Cancer Among Patients With Hypertension From the Korean National Health Insurance Service-National Health Screening Cohort
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives: The objective of this study was to estimate the risk of lung cancer in relation to angiotensin II receptor blocker (ARB) use among patients with hypertension from the Korean National Health Insurance Service-National Health Screening Cohort. Methods: We conducted a retrospective cohort study of patients with hypertension who started to take antihypertensive medications and had a treatment period of at least 6 months. We calculated the weighted hazard ratios (HRs) and their 95% confidence intervals (CIs) of lung cancer associated with ARB use compared with calcium channel blocker (CCB) use using inverse probability treatment weighting. Results: Among a total of 60 469 subjects with a median follow-up time of 7.8 years, 476 cases of lung cancer were identified. ARB use had a protective effect on lung cancer compared with CCB use (HR, 0.75; 95% CI, 0.59 to 0.96). Consistent findings were found in analyses considering patients who changed or discontinued their medication (HR, 0.50; 95% CI, 0.32 to 0.77), as well as for women (HR, 0.56; 95% CI, 0.34 to 0.93), patients without chronic obstructive pulmonary disease (HR, 0.75; 95% CI, 0.56 to 1.00), never-smokers (HR, 0.64; 95% CI, 0.42 to 0.99), and non-drinkers (HR, 0.69; 95% CI, 0.49 to 0.97). In analyses with different comparison antihypertensive medications, the overall protective effects of ARBs on lung cancer risk remained consistent. Conclusions: The results of the present study suggest that ARBs could decrease the risk of lung cancer. More evidence is needed to establish the causal effect of ARBs on the incidence of lung cancer.
Abstract
Objectives: The objective of this study was to estimate the risk of lung cancer in relation to angiotensin II receptor blocker (ARB) use among patients with hypertension from the Korean National Health Insurance Service-National Health Screening Cohort. Methods: We conducted a retrospective cohort study of patients with hypertension who started to take antihypertensive medications and had a treatment period of at least 6 months. We calculated the weighted hazard ratios (HRs) and their 95% confidence intervals (CIs) of lung cancer associated with ARB use compared with calcium channel blocker (CCB) use using inverse probability treatment weighting. Results: Among a total of 60 469 subjects with a median follow-up time of 7.8 years, 476 cases of lung cancer were identified. ARB use had a protective effect on lung cancer compared with CCB use (HR, 0.75; 95% CI, 0.59 to 0.96). Consistent findings were found in analyses considering patients who changed or discontinued their medication (HR, 0.50; 95% CI, 0.32 to 0.77), as well as for women (HR, 0.56; 95% CI, 0.34 to 0.93), patients without chronic obstructive pulmonary disease (HR, 0.75; 95% CI, 0.56 to 1.00), never-smokers (HR, 0.64; 95% CI, 0.42 to 0.99), and non-drinkers (HR, 0.69; 95% CI, 0.49 to 0.97). In analyses with different comparison antihypertensive medications, the overall protective effects of ARBs on lung cancer risk remained consistent. Conclusions: The results of the present study suggest that ARBs could decrease the risk of lung cancer. More evidence is needed to establish the causal effect of ARBs on the incidence of lung cancer.
참고문헌 (40)
- Bray F, "Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 68(6), pp.394~424 (2018)
- 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2016", Cancer Research and Treatment, 51(2), pp.417~430 (2019), 대한암학회
- Korean Society Hypertension (KSH), "Korea hypertension fact sheet 2018", Clin Hypertens, 24, pp.13~ (2018)
- Peach MJ, "Renin-angiotensin system : biochemistry and mechanisms of action", Physiol Rev, 57(2), pp.313~370 (1977)
- George AJ, "The renin-angiotensin system and cancer : old dog, new tricks", Nat Rev Cancer, 10(11), pp.745~759 (2010)
- Wegman-Ostrosky T, "The renin-angiotensin system meets the hallmarks of cancer", J Renin Angiotensin Aldosterone Syst, 16(2), pp.227~233 (2015)
- Xu J, "The ACE2", angiotensin-(1-7), Front Physiol, pp.2017, 8[DOI]
- Ager EI, "The renin-angiotensin system and malignancy", Carcinogenesis, 29(9), pp.1675~1684 (2008)
- Gallagher PE, "Angiotensin-(1-7) : a peptide hormone with anti-cancer activity", Curr Med Chem, 21(21), pp.2417~2423 (2014)
- Bhaskaran K, "Angiotensin receptor blockers and risk of cancer : cohort study among people receiving antihypertensive drugs in UK General Practice Research Database", BMJ, 344, pp.e2697~ (2012)
- Wang KL, "Long-term use of angiotensin II receptor blockers and risk of cancer : a population-based cohort analysis", Int J Cardiol, 167(5), pp.2162~2166 (2013)
- Lin SY, "Association between angiotensin-converting enzyme inhibitors and lung cancer-a nationwide, population-based, propensity score-matched cohort study", Cancers(Basel), 12(3), pp.747~ (2020)
- Shrank WH, "Healthy user and related biases in observational studies of preventive interventions : a primer for physicians", J Gen Intern Med, 26(5), pp.546~550 (2011)
- Zhang J, "Angiotensin receptor blockers(ARBs)reduce the risk of lung cancer : a systematic review and meta-analysis", Int J Clin Exp Med, 8(8), pp.12656~12660 (2015)
- Datzmann T, "Systematic review and meta-analysis of randomised controlled clinical trial evidence refutes relationship between pharmacotherapy with angiotensin-receptor blockers and an increased risk of cancer", Eur J Intern Med, 64, pp.1~9 (2019)
- Seong SC, "Cohort profile : the National Health Insurance Service-National Health Screening Cohort(NHIS-HEALS)in Korea", BMJ Open, 7(9), pp.e016640~ (2017)
- Lund JL, "The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application", Curr Epidemiol Rep, 2(4), pp.221~228 (2015)
- D’Arcy M, "The importance and implications of comparator selection in pharmacoepidemiologic research", Curr Epidemiol Rep, 5(3), pp.272~283 (2018)
- Roberts AW, "Revisiting the washout period in the incident user study design : why 6-12 months may not be sufficient", J Comp Eff Res, 4(1), pp.27~35 (2015)
- Lee HY, "The Korean Society of Hypertension guidelines for the management of hypertension in 2013: its essentials and key points", Pulse (Basel), 3(1), pp.21~28 (2015)
- Grimaldi-Bensouda L, "Calcium channel blockers and cancer : a risk analysis using the UK Clinical Practice Research Datalink(CPRD)", BMJ Open, 6(1), pp.e009147~ (2016)
- Rosenberg L, "Calcium channel blockers and the risk of cancer", JAMA, 279(13), pp.1000~1004 (1998)
- Pottegård A, "Considerations for pharmacoepidemiological studies of drug-cancer associations", Basic Clin Pharmacol Toxicol, 122(5), pp.451~459 (2018)
- Htoo PT, "Renin-angiotensin-aldosterone system-based antihypertensive agents and the risk of colorectal cancer among medicare beneficiaries", Epidemiology, 30(6), pp.867~875 (2019)
- Seo HJ, "A comparison of the cancer incidence rates between the national cancer registry and insurance claims data in Korea", Asian Pac J Cancer Prev, 13(12), pp.6163~6168 (2012)
- Rosenbaum PR, "The central role of the propensity score in observational studies for causal effects", Biometrika, 70(1), pp.41~55 (1983)
- Austin PC, "Moving towards best practice when using inverse probability of treatment weighting(IPTW)using the propensity score to estimate causal treatment effects in observational studies", Stat Med, 34(28), pp.3661~3679 (2015)
- Charlson ME, "A new method of classifying prognostic comorbidity in longitudinal studies : development and validation", J Chronic Dis, 40(5), pp.373~383 (1987)
- Xu S, "Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals", Value Health, 13(2), pp.273~277 (2010)
- Austin PC, "An introduction to propensity score methods for reducing the effects of confounding in observational studies", Multivariate Behav Res, 46(3), pp.399~424 (2011)
- Austin PC, "Variance estimation when using inverse probability of treatment weighting(IPTW)with survival analysis", Stat Med, 35(30), pp.5642~5655 (2016)
- Malhotra J, "Risk factors for lung cancer worldwide", Eur Respir J, 48(3), pp.889~902 (2016)
- Rotshild V, "The risk for lung cancer incidence with calcium channel blockers : a systematic review and meta-analysis of observational studies", Drug Saf, 41(6), pp.555~564 (2018)
- Seretis A, "Association between blood pressure and risk of cancer development : a systematic review and meta-analysis of observational studies", Sci Rep, 9(1), pp.8565~ (2019)
- Catarata MJ, "Renin-angiotensin system in lung tumor and microenvironment interactions", Cancers(Basel), 12(6), pp.1457~ (2020)
- Nehme A, "An update on the tissue renin angiotensin system and its role in physiology and pathology", J Cardiovasc Dev Dis, 6(2), pp.14~ (2019)
- Ferrario CM, "Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2", Circulation, 111(20), pp.2605~2610 (2005)
- Pazzagli L, "Methods for time-varying exposure related problems in pharmacoepidemiology : An overview", Pharmacoepidemiol Drug Saf, 27(2), pp.148~160 (2018)
- Hernán MA, "Using big data to emulate a target trial when a randomized trial is not available", Am J Epidemiol, 183(8), pp.758~764 (2016)
- Lévesque LE, "Problem of immortal time bias in cohort studies : example using statins for preventing progression of diabetes", BMJ, 340, pp.b5087~ (2010)